Results 121 to 130 of about 136,614 (358)

A Quantitative Systems Pharmacology (QSP) Model of Acute Hepatitis B Virus Infection: Mechanistic Insights and Foundations for Future Extensions

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Chronic hepatitis B virus (HBV) infection remains a significant global health challenge. While the dynamic interplay between viral replication and host immune responses determines infection outcomes, the mechanisms driving the resolution of acute infection versus the emergence of chronicity remain incompletely understood.
Clémence Boivin‐Champeaux, Stephan Schmidt, Scott Balsitis, Francine Johansson Azeredo, Justin S. Feigelman   +4 more
wiley   +1 more source

Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy

United European Gastroenterology Journal, Volume 14, Issue 1, February 2026.
ABSTRACT Background Chronic delta hepatitis represents a major health burden. Until recently, pegylated interferon‐alfa‐2a (PEG‐IFNα) therapy was the only treatment option for patients infected with hepatitis D virus (HDV). The aim of this study was to evaluate 10‐year long‐term clinical and virological outcomes after 96 weeks of treatment with PEG ...
Cihan Yurdaydin, Julia Kahlhöfer, Florin Alexandru Caruntu, Kendal Yalcin, Selim Gürel, Ulus S. Akarca, Kathrin Sprinzl, Hans H. Bock, Jan‐Hendrik Bockmann, George V. Papatheodoridis, Uta Merle, Münevver Demir, Svenja Hardtke, Onur Keskin, Ramazan Idilman, Markus Cornberg, Heiner Wedemeyer, Anika Wranke   +17 more
wiley   +1 more source

Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations [PDF]

, 1990
The morphologic evolution of hepatitis B virus (HBV) liver disease in 45 hepatic allograft recipients who were HBV surface-antigen positive (HBs-Ag+) at the time of liver replacement and who survived for more than 60 days was studied by routine ...
Demetris, AJ, Fung, JJ, Iwaki, Y, Ming, W, Starzl, TE, Sysyn, G, Todo, S, Trager, J, Van Thiel, DH   +8 more
core   +1 more source

Artificial neural network accurately predicts hepatitis B surface antigen seroclearance [PDF]

, 2014
BACKGROUND & AIMS: Hepatitis B surface antigen (HBsAg) seroclearance and seroconversion are regarded as favorable outcomes of chronic hepatitis B (CHB).
Fong, DYT, Fung, JYY, Hung, IFN, Lai, CL, Seto, WKW, Shi, KQ, Tong, T, Wong, DKH, Yuen, JCH, Yuen, RMF, Zheng, MH   +10 more
core   +1 more source

P1‐135: Molecular detection of Hepatitis B virus (HBV) DNA among Hepatitis B Surface antigen (HBsAg) Negative Blood Donors in Angola [PDF]

, 2018

openalex   +1 more source

HBsAg in Cord Blood Qf Newborns of HBsAg-Positive Mothers

Paediatrica Indonesiana, 2018
Vertical transmission of hepatitis B infection that may occur during pregnancy at delivery-, in infancy, and early childhood has an important role in the development of chronic hepatitis B. Intrauterine infection is suspected to occur when hepatitis B viruses cross the placenta into fetal circulation due to failure of placental tissue function.
Asri Rasad, Triyatmo Rachimhadhi, H. M. Sjaifullah Noer, Evi Setiadi, Adnan S. Wiharta   +4 more
openaire   +2 more sources

Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 374-382, February 2026.
This study evaluated the performance of the PAGE‐B score in HCC risk among CHB patients with metabolic dysfunction or MASLD. The PAGE‐B score effectively stratified HCC risk in both MASLD and non‐MASLD patients, especially in those without cirrhosis, where low scores were linked to negligible 5‐year HCC risk. ABSTRACT Introduction Metabolic dysfunction
Lesley A. Patmore, Ivana Carey, Jordan J. Feld, Willem P. Brouwer, Keyur Patel, Maria Buti, Pieter Honkoop, Douwe F. Postma, Hans Blokzijl, Özgur. M. Koc, Eva van Oorschot, Kosh Agarwal, Marc van der Valk, Faydra I. Lieveld, Mai Kilany, Matthijs Kramer, Joep de Bruijne, Mark A. A. Claassen, Bettina E. Hansen, Robert A. de Man, Harry L. A. Janssen, R. Bart Takkenberg, Milan J. Sonneveld   +22 more
wiley   +1 more source

To the problem of extended serological testing for viral hepatitis B in rheumatoid arthritis patients

Терапевтический архив
Aim. The objectives of the study: to conduct serologic screening for latent HBV infection in rheumatoid arthritis (RA) patients, to determine the level of protective antibodies to HBsAg in RA patients, and to determine the clinical and laboratory ...
Galina I. Gridneva, Boris S. Belov, Zhanna G. Verizhnikova, Evgeniia S. Aronova, Elena Yu. Samarkina, Taras S. Panevin, Tatiana A. Lisitsyna, Galina V. Lukina   +7 more
doaj   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 383-395, February 2026.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Erişkin HBsAg Pozitif Hastalarda Hepatit A Seroprevalansı

Genel Tıp Dergisi, 2020
Amaç: Hepatit A virüs HAV nadiren fulminan hepatite neden olmakla beraber, özellikle viral hepatit kronik karaciğer hastalığı olan kişilerde görülebilen HAV ko-enfeksiyonu daha ciddi klinik tablolara neden olabilir.
Alper Tahmaz, Süleyman Sırrı Kılıç, Özgür Günal, Sevil Alkan Çeviker   +3 more
doaj